knowledge -WSS

knowledge

author：entertainment 2025-08-06 04:47:22 - browse：969

Americans who suffer severe allergic reactions won’t have alternatives to auto-injectors like the EpiPen for a while longer. In a surprise move, the Food and Drug Administration on Tuesday declined to approve neffy, an epinephrine nasal spray. Instead, the FDA asked the drug’s manufacturer, ARS Pharma, to conduct further studies, specifically comparing the effect of repeat doses of epinephrine administered via nasal spray versus auto-injection in people with allergic rhinitis, or hay fever.

This was unexpected, and disappointing, for ARS Pharma: In May, an FDA advisory committee had voted 16-6 in favor of neffy’s approval for adults, and 17-5 in favor for children. But there is at least one party that’s likely to benefit from this development: Viatris, the maker of EpiPen, the brand-name epinephrine auto-injector used to treat anaphylaxis. (A generic version is also available, made by Teva).

In June, Viatris filed a citizen petition with the FDA, saying that the available evidence left doubts about how neffy would actually perform in a real-life anaphylactic event compared to auto-injectable epinephrine.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Idaho college killings prosecutors challenge defense's grand jury claims

focus

WSS

Illinois Supreme Court finds assault weapons ban constitutional

The EPA's new lead rule: How one expert crunched the numbers

Illinois Supreme Court finds assault weapons ban constitutional

Illumina slashes 2023 revenue projections yet again

Hospitals are dialing back on venture capital investing

Rep. Raul Ruiz on the physician shortage and more

focus

knowledge

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Aspartame and sugar

Virginia high school admissions case could be legal follow

The EPA's new lead rule: How one expert crunched the numbers

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Walensky prepares to leave CDC — and Congress — behind

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

How one medical school became remarkably diverse

Patients, digital health players weigh in on FTC's data privacy plan

focus

Novo Nordisk touts Wegovy study, but still struggling with supply

Will the market for weight loss drugs really reach $100 billion?

30 years of 'Listening to Prozac'

Dozens dead from Maui wildfires: What we know about the victims

Illinois Supreme Court finds assault weapons ban constitutional

J&J to emphasize cancer drugs, stop much of its vaccine research

Wikipedia

explore

focus

explore